pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

22 catalysts · 4 phase 2 completion · 4 phase 2 initiation · 4 phase 3 initiation · 3 phase 1 completion · 2 phase iv trial initiation · 2 phase 1 initiation

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 97 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
TA: immunology×TA: pulmonology×to 2026-04-27×clear all
type
  • phase 2 completion4
  • phase 2 initiation4
  • phase 3 initiation4
  • phase 1 completion3
  • phase iv trial initiation2
  • phase 1 initiation2
  • phase 3 completion1
  • patent expiry1
  • drug expiry1
  • therapy area
    • Oncology41
    • Infectious Disease17
    • Dermatology16
    • Immunology14
    • Women's Health9
    • Pulmonology8
    • Cardiology8
    • Pain7
    • Ophthalmology6

    Week of Apr 20, 2026

    16
    ›Apr 24, 2026patent expiry110d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026drug expiry110d agoDaiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026phase 1 initiation110d agoBeijing Friendship Hospital — CMSD-001 (Phase I Trial Initiation)CMSD-001

    Therapy area: Dermatology, Immunology. Indication: Atopic Dermatitis (Atopic Eczema), Plaque Psoriasis (Psoriasis Vulgaris), Systemic Lupus Erythematosus

    full page →CMSD-001 →source: globaldata
    ›Apr 24, 2026phase 2 completion110d agoAlentis Therapeutics AG — lixudebart (Phase II Trial Completion)lixudebart

    Therapy area: Genito Urinary System, Immunology. Indication: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Glomerulonephritis, Kidney Fibrosis

    full page →lixudebart →source: globaldata
    ›Apr 24, 2026phase iv trial initiation110d agoPeople's College of Medical Sciences & Research Centre — formoterol (Phase IV Trial Initiation)formoterol

    Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

    full page →formoterol →source: globaldata
    ›Apr 24, 2026phase iv trial initiation110d agoAll India Institute of Medical Sciences Jodhpur — melatonin (Phase IV Trial Initiation)melatonin

    Therapy area: Central Nervous System, Immunology. Indication: Delirium, Inflammation

    full page →melatonin →source: globaldata
    ›Apr 25, 2026phase 1 completion109d agoBristar Immunotech Biotechnology Co Ltd — YTS-109 (Phase I Trial Completion)YTS-109

    Therapy area: Hematological Disorders, Immunology. Indication: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Thrombocytopenia

    full page →YTS-109 →source: globaldata
    ›Apr 25, 2026phase 2 completion109d agoNational Institute of Siddha — undisclosed siddha medicine (Phase II Trial Completion)undisclosed siddha medicine

    Therapy area: Respiratory. Indication: Asthma

    full page →undisclosed siddha medicine →source: globaldata
    ›Apr 25, 2026phase 2 completion109d agoEmami Ltd — Himani fast relief gel (Phase II Trial Completion)Himani fast relief gel

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders. Indication: Inflammation, Myalgia (Muscle Pain), Unspecified Musculoskeletal Disorders

    full page →Himani fast relief gel →source: globaldata
    ›Apr 25, 2026phase 2 initiation109d agoKIMS Hospital — bifidobacterium (Phase II Trial Initiation)bifidobacterium

    Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

    full page →bifidobacterium →source: globaldata
    ›Apr 25, 2026phase 3 initiation109d agoDr. Reddy's Laboratories Ltd — olokizumab (Phase III Trial Initiation)olokizumab

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →olokizumab →source: globaldata
    ›Apr 26, 2026phase 2 completion108d agoUniversity Health Network — decidual stromal cells (Phase II Trial Completion)decidual stromal cells

    Therapy area: Immunology. Indication: Graft Versus Host Disease (GVHD)

    full page →decidual stromal cells →source: globaldata
    ›Apr 26, 2026phase 2 initiation108d agoTianFang Pharmaceutical Co — diclofenac sodium DR (Phase II Trial Initiation)DICLOFENAC SODIUM

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Dental Pain (Toothache/Tooth Pain), Dysmenorrhea, Gouty Arthritis (Gout), Injury, Myalgia (Muscle Pain), Osteoarthritis, Pain, Post-Operative Pain, Rheumatic Disorders, Rheumatoid Arthritis, Spondyloarthritis (Spondyloarthropathy), Tenosynovitis

    full page →DICLOFENAC SODIUM →source: globaldata
    ›Apr 26, 2026phase 2 initiation108d agoStarmab Biology (Suzhou) Co Ltd — XJ-103 (Phase II Trial Initiation)XJ-103

    Therapy area: Respiratory. Indication: Streptococcal Pneumonia

    full page →XJ-103 →source: globaldata
    ›Apr 26, 2026phase 3 completion108d agoHomi Bhabha Cancer Hospital Research Centre — megestrol (Phase III Trial Completion)megestrol

    Therapy area: Central Nervous System, Gastrointestinal, Genito Urinary System, Respiratory. Indication: Anorexia Nervosa, Unspecified Gastrointestinal Disorders, Unspecified Genito Urinary Disorders, Unspecified Respiratory Disorders

    full page →megestrol →source: globaldata
    ›Apr 26, 2026phase 3 initiation108d agoStanford University — zanubrutinib (Phase III Trial Initiation)zanubrutinib

    Therapy area: Immunology. Indication: Immunoglobulin G4-Related Disease (IgG4-RD)

    full page →zanubrutinib →source: globaldata

    Week of Apr 27, 2026

    6
    ›Apr 27, 2026phase 1 completion107d agoCTI Clinical Trial and Consulting Services Australia Pty Ltd — PTC-844 (Phase I Trial Completion)PTC-844

    Therapy area: Immunology. Indication: Unspecified Immunological Disorders

    full page →PTC-844 →source: globaldata
    ›Apr 27, 2026phase 1 completion
    107d ago
    Fortrea Holdings Inc — balinatunfib (Phase I Trial Completion)balinatunfib

    Therapy area: Gastrointestinal, Immunology. Indication: Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Ulcerative Colitis

    full page →balinatunfib →source: globaldata
    ›Apr 27, 2026phase 1 initiation107d agoNational Heart Lung and Blood Institute — fostamatinib (Phase I Trial Initiation)fostamatinib

    Therapy area: Immunology. Indication: Liver Transplant Rejection

    full page →fostamatinib →source: globaldata
    ›Apr 27, 2026phase 2 initiation107d agoTianjin Lisheng Pharmaceutical Co Ltd — aminophylline (Phase II Trial Initiation)aminophylline

    Therapy area: Cardiovascular, Respiratory. Indication: Asthma, Bronchitis, Emphysema, Pulmonary Edema

    full page →aminophylline →source: globaldata
    ›Apr 27, 2026phase 3 initiation107d agoUniversity of Thessaly — abatacept (Phase III Trial Initiation)abatacept

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →abatacept →source: globaldata
    ›Apr 27, 2026phase 3 initiation107d agoGan & Lee Pharmaceuticals Co Ltd — bofanglutide (Phase III Trial Initiation)bofanglutide

    Therapy area: Respiratory. Indication: Obstructive Sleep Apnea

    full page →bofanglutide →source: globaldata
    $FTRE19.52+2.79%